Maki Ando
Impact in
- Nephrology top 5%
- Renal Diseases and Glomerulopathies
- Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism
Papers in
- Oncology 7
- Lung Cancer Research Studies 4
- Neutropenia and Cancer Infections 3
-
- Neonatal Health and Biochemistry 5
- Co-authors
- Yoshinori Hasegawa (10 shared papers)Yukio Ando (10 shared papers)Kaoru Shimokata (8 shared papers)Hideo Saka (5 shared papers)Kei Muro (1 shared paper)Soh Saitoh (1 shared paper)Toshiyuki Sawa (1 shared paper)Hiroshi Ueoka (1 shared paper)
- Journals
- Nephrology Dialysis Transplantation (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)Respiration (1 paper)Pharmacogenetics and Genomics (1 paper)Clinical Chemistry (1 paper)
- Partner nations
- JapanUnited StatesChina
In The Last Decade
Maki Ando
18 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 75
- Nephrology 234
- Pharmacology 195
- Oncology 486
- Pediatrics, Perinatology and Child Health 201
- Molecular Biology 557
Countries citing papers authored by Maki Ando
This map shows the geographic impact of Maki Ando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maki Ando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maki Ando more than expected).
Fields of papers citing papers by Maki Ando
This network shows the impact of papers produced by Maki Ando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maki Ando. The network helps show where Maki Ando may publish in the future.
Co-authors
The 25 scholars most cited alongside Maki Ando, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. | 2000 | 656 |
| 2 | 2009 | 211 | |
| 3 | 2008 | 53 | |
| 4 | 2005 | 52 | |
| 5 | 2002 | 51 | |
| 6 | Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. | 2000 | 40 |
| 7 | 2012 | 39 | |
| 8 | 2004 | 39 | |
| 9 | 2001 | 35 | |
| 10 | Pharmacological analysis of etoposide in elderly patients with lung cancer. | 1999 | 33 |
| 11 | 2005 | 24 | |
| 12 | 2005 | 12 | |
| 13 | 2006 | 11 | |
| 14 | 2004 | 9 | |
| 15 | 2014 | 9 | |
| 16 | 2001 | 8 | |
| 17 | A double-blind comparative study of prulifloxacin and ofloxacin in lower chronic respiratory tract infections | 1997 | 1 |
| 18 | 2022 | 1 |
About Maki Ando
Maki Ando is a scholar working on Oncology, Pediatrics, Perinatology and Child Health, Nephrology, Pharmacology and Pulmonary and Respiratory Medicine, having authored 18 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (6 papers), Neonatal Health and Biochemistry (5 papers), Lung Cancer Research Studies (4 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers), Neutropenia and Cancer Infections (3 papers), Renal Diseases and Glomerulopathies (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Pneumocystis jirovecii pneumonia detection and treatment (1 paper). The work is most often cited by research in Nephrology (234 citations), Pharmacology (195 citations), Oncology (486 citations), Pediatrics, Perinatology and Child Health (201 citations) and Molecular Biology (557 citations). Maki Ando has collaborated with scholars based in Japan, United States and China. Frequent co-authors include Yoshinori Hasegawa, Yukio Ando, Kaoru Shimokata, Hideo Saka, Kei Muro, Soh Saitoh, Toshiyuki Sawa, Hiroshi Ueoka, Akira Yokoyama and Masaki Goto. Their work appears in journals such as Nephrology Dialysis Transplantation, Cancer Chemotherapy and Pharmacology, Respiration, Pharmacogenetics and Genomics and Clinical Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.